uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Consistent mutation status within histologically heterogeneous lung cancer lesions
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Molekylär och morfologisk patologi. (botling)
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för genetik och patologi, Molekylär och morfologisk patologi. (botling)
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Molekylär och morfologisk patologi.
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Molekylär och morfologisk patologi. (botling)
Vise andre og tillknytning
2012 (engelsk)Inngår i: Histopathology, ISSN 0309-0167, E-ISSN 1365-2559, Vol. 61, nr 4, s. 744-748Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Aims: Activating epidermal growth factor receptor (EGFR) and KRAS mutations characterize molecular subgroups of non-small-cell lung cancer (NSCLC) with a strong predictive value for response to EGFR inhibitor therapy. However, the temporal occurrence and clonal stability of these mutations during the course of cancer progression are debated. The aim of this study was to characterize the presence of EGFR and KRAS mutations in histologically different areas of primary NSCLC lesions. Methods and results: Formalin-fixed paraffin-embedded cancer specimens from six cases with EGFR mutations and five cases with KRAS mutations were selected from a pool of primary resected NSCLC patients. From each tumour, three morphologically distinct areas were manually microdissected and analysed for the presence of mutations. The results demonstrated consistent EGFR and KRAS mutation status in the different histological areas of all primary tumours. Conclusions: The results support the concept that activating EGFR and KRAS mutations are oncogenic events that are consistently present throughout the primary tumour independently of histological heterogeneity. Thus, for molecular diagnostics, any part of the tumour is likely to be representative for EGFR and KRAS mutation testing.

sted, utgiver, år, opplag, sider
2012. Vol. 61, nr 4, s. 744-748
Emneord [en]
EGFR, heterogeneity, KRAS, lung cancer, molecular testing, mutation analysis
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-187099DOI: 10.1111/j.1365-2559.2012.04245.xISI: 000310481800022OAI: oai:DiVA.org:uu-187099DiVA, id: diva2:573975
Tilgjengelig fra: 2012-12-04 Laget: 2012-12-03 Sist oppdatert: 2019-10-07

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekst

Personposter BETA

Mattsson, Johanna Sofia MargaretaEdlund, KarolinaBotling, JohanMicke, Patrick

Søk i DiVA

Av forfatter/redaktør
Mattsson, Johanna Sofia MargaretaImgenberg-Kreuz, JulianaEdlund, KarolinaBotling, JohanMicke, Patrick
Av organisasjonen
I samme tidsskrift
Histopathology

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 718 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf